Shares of Curis jumped after the company released what it assessed as positive data from a study of its in-development treatment for leukemia. The stock was up 33%, to $4.07, in midday trading ...
Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.